Trial reportJournal of the American Society of Nephrology : JASN2026
Genetic Determinants of Steroid Responsiveness in IgA Nephropathy.
Trial report in Journal of the American Society of Nephrology : JASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Complement Genomics and Steroid Pharmacogenomics Define Heterogeneity in Progression and Treatment of IgA Nephropathy.Journal of the American Society of Nephrology : JASN · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
key pointsGenetic variant rs477155 near cytidine deaminase identified IgA nephropathy patients with enhanced glucocorticoid response. rs477155 may regulate cytidine deaminase via glucocorticoid receptor, linking genomic variation to steroid sensitivity and individualized treatment optimization.
backgroundGlucocorticoid therapy improves outcomes in high-risk IgA nephropathy but shows variable efficacy and adverse effects, potentially influenced by genetic factors.
methodsWe conducted a genome-wide pharmacogenomic analysis in 260 biopsy-confirmed patients with IgA nephropathy from the Chinese The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) study cohort (134 received methylprednisolone and 126 received placebo), assessing the percentage reduction in 24-hour proteinuria at 6 months via genotype-by-treatment interaction models. Replication was performed in an independent cohort of 211 high-risk patients receiving glucocorticoid monotherapy. Functional annotation, expression quantitative trait loci mapping, regulatory analyses, and dual-luciferase reporter assays elucidated the biologic relevance of candidate loci.
resultsGenome-wide analysis identified three loci with suggestive genotype-by-treatment interaction ( P < 5.00×10 -6 ), of which rs477155 (chromosome 1, intronic to cytidine deaminase [ CDA ]) was replicated in the independent cohort (discovery P = 2.70×10 -6 , replication P = 0.01). In the TESTING study cohort, carriers of the rs477155 GG genotype had significantly higher rates of complete proteinuria remission (odds ratio, 2.5; 95% confidence interval, 1.3 to 4.9; P = 5.00×10 -3 ) and composite clinical remission (odds ratio, 2.8; 95% confidence interval, 1.6 to 4.9; P = 3.13×10 -4 ) at 6 months. Functional analyses revealed that rs477155 acts as a Cis -expression quantitative trait locus for CDA in blood and immune cells and is located within an enhancer region marked by H3K4Me1/H3K27Ac and a glucocorticoid receptor (nuclear receptor subfamily 3 group C member 1 [NR3C1])-binding site. Bioinformatics, dual-luciferase reporter assay, and RNA-seq analyses indicated that NR3C1 may directly regulate CDA expression, with rapid upregulation of CDA observed in blood after dexamethasone stimulation (9.84±0.52 versus 10.50±0.55, P = 7.41×10 -23 ). Phenome-wide association studies further linked rs477155 and CDA to a spectrum of immune and kidney traits, including acute tubulointerstitial nephritis ( P = 7.4×10 -11 ), nephritic syndrome ( P = 2.7×10 -8 ), asthma ( P = 2.5×10 -21 ), and rheumatoid arthritis ( P = 2.1×10 -12 ).
conclusionsIn this study, rs477155 was suggestively associated with glucocorticoid responsiveness in IgA nephropathy, potentially via a suggested NR3C1-regulated CDA pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.